$589.48
1.45% today
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US75886F1075
Symbol
REGN

Regeneron Pharmaceuticals Target price 2025 - Analyst rating & recommendation

Regeneron Pharmaceuticals Classifications & Recommendation:

Buy
74%
Hold
24%
Sell
3%

Regeneron Pharmaceuticals Price Target

Target Price $762.52
Price $589.48
Potential 29.35%
Number of Estimates 28
28 Analysts have issued a price target Regeneron Pharmaceuticals 2026 . The average Regeneron Pharmaceuticals target price is $762.52. This is 29.35% higher than the current stock price. The highest price target is $1,063.65 80.44% , the lowest is $548.43 6.96% .
A rating was issued by 34 analysts: 25 Analysts recommend Regeneron Pharmaceuticals to buy, 8 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Regeneron Pharmaceuticals stock has an average upside potential 2026 of 29.35% . Most analysts recommend the Regeneron Pharmaceuticals stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032


Dec '24 2025
Estimates
Revenue Billion $ 14.20 13.66
8.27% 3.84%
EBITDA Margin 33.10% 33.39%
8.72% 0.88%
Net Margin 31.07% 28.12%
3.08% 9.50%

29 Analysts have issued a sales forecast Regeneron Pharmaceuticals 2025 . The average Regeneron Pharmaceuticals sales estimate is $13.7b . This is 3.92% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $14.9b 4.92% , the lowest is $12.2b 14.24% .

This results in the following potential growth metrics:

Revenue Estimates

2024 $14.2b 8.27%
2025 $13.7b 3.84%
2026 $14.6b 6.65%
2027 $16.1b 10.67%
2028 $17.0b 5.40%
2029 $17.9b 5.58%
2030 $18.7b 4.38%
2031 $19.3b 3.28%
2032 $18.8b 2.77%

14 Analysts have issued an Regeneron Pharmaceuticals EBITDA forecast 2025. The average Regeneron Pharmaceuticals EBITDA estimate is $4.6b . This is 0.21% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $6.3b 37.21% , the lowest is $3.1b 31.57% .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $4.7b 1.17%
2025 $4.6b 3.00%
2026 $5.3b 15.92%
2027 $6.1b 15.49%
2028 $6.4b 4.95%
2029 $7.1b 11.19%
2030 $7.7b 7.71%
2031 $8.0b 4.42%
2032 $7.1b 11.00%

EBITDA Margin

2024 33.10% 8.72%
2025 33.39% 0.88%
2026 36.29% 8.69%
2027 37.87% 4.35%
2028 37.71% 0.42%
2029 39.72% 5.33%
2030 40.98% 3.17%
2031 41.44% 1.12%
2032 37.93% 8.47%

30 Regeneron Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Regeneron Pharmaceuticals net profit estimate is $3.8b . This is 13.86% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $4.7b 6.12% , the lowest is $3.2b 28.93% .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $4.4b 11.61%
2025 $3.8b 12.96%
2026 $4.3b 11.59%
2027 $5.3b 22.75%
2028 $5.8b 9.86%
2029 $6.4b 10.14%
2030 $6.9b 7.98%
2031 $7.4b 7.19%
2032 $7.1b 3.13%

Net Margin

2024 31.07% 3.08%
2025 28.12% 9.50%
2026 29.43% 4.66%
2027 32.64% 10.91%
2028 34.02% 4.23%
2029 35.49% 4.32%
2030 36.72% 3.47%
2031 38.11% 3.79%
2032 37.97% 0.37%

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032


Dec '24 2025
Estimates
Earnings Per Share $ 38.34 36.10
10.27% 5.84%
P/E 16.57
EV/Sales 4.29

30 Analysts have issued a Regeneron Pharmaceuticals forecast for earnings per share. The average Regeneron Pharmaceuticals EPS is $36.10 . This is 12.06% lower than earnings per share in the financial year 2024. The highest EPS forecast is $44.47 8.33% , the lowest is $29.78 27.45% .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $38.34 10.27%
2025 $36.10 5.84%
2026 $40.28 11.58%
2027 $49.45 22.77%
2028 $54.32 9.85%
2029 $59.83 10.14%
2030 $64.61 7.99%
2031 $69.25 7.18%
2032 $67.09 3.12%

P/E ratio

Current 14.57 53.74%
2025 16.57 13.72%
2026 14.85 10.38%
2027 12.10 18.52%
2028 11.01 9.01%
2029 10.00 9.17%
2030 9.26 7.40%
2031 8.64 6.70%
2032 8.92 3.24%

Based on analysts' sales estimates for 2025, the Regeneron Pharmaceuticals stock is valued at an EV/Sales of 4.29 and an P/S ratio of 4.64 .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.12 54.77%
2025 4.29 4.21%
2026 4.03 6.24%
2027 3.64 9.64%
2028 3.45 5.12%
2029 3.27 5.29%
2030 3.13 4.19%
2031 3.03 3.18%
2032 3.12 2.85%

P/S ratio

Current 4.46 53.72%
2025 4.64 4.08%
2026 4.35 6.23%
2027 3.93 9.64%
2028 3.73 5.12%
2029 3.53 5.28%
2030 3.39 4.19%
2031 3.28 3.18%
2032 3.37 2.85%

Current Regeneron Pharmaceuticals Upgrades & Downgrades

Analyst Rating Action Date
Truist Securities
Buy
Buy
Unchanged Aug 11 2025
BMO Capital
Outperform
Outperform
Unchanged Aug 04 2025
RBC Capital
Sector Perform
Sector Perform
Unchanged Aug 04 2025
Morgan Stanley
Overweight
Overweight
Unchanged Aug 04 2025
Guggenheim
Buy
Buy
Unchanged Aug 04 2025
Canaccord Genuity
Buy
Buy
Unchanged Jul 23 2025
UBS
Neutral
Neutral
Unchanged Jul 11 2025
Analyst Rating Date
Unchanged
Truist Securities:
Buy
Buy
Aug 11 2025
Unchanged
BMO Capital:
Outperform
Outperform
Aug 04 2025
Unchanged
RBC Capital:
Sector Perform
Sector Perform
Aug 04 2025
Unchanged
Morgan Stanley:
Overweight
Overweight
Aug 04 2025
Unchanged
Guggenheim:
Buy
Buy
Aug 04 2025
Unchanged
Canaccord Genuity:
Buy
Buy
Jul 23 2025
Unchanged
UBS:
Neutral
Neutral
Jul 11 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today